Risk scores did not reliably predict individual risk of mortality for patients with decompensated heart failure.


Journal

Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383

Informations de publication

Date de publication:
09 2020
Historique:
received: 05 11 2019
revised: 08 05 2020
accepted: 20 05 2020
pubmed: 29 5 2020
medline: 5 3 2021
entrez: 29 5 2020
Statut: ppublish

Résumé

We investigated the performance of four prognostic tools in predicting 180-day mortality for patients admitted for acute decompensated heart failure (ADHF) by calculating sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) over a range of risk thresholds, in addition to discrimination and calibration. We studied 1,458 patients. The risk assessment was performed using the Acute Decompensated Heart Failure National Registry (ADHERE) model and the Get With The Guidelines (GWTG), ADHF/NT-proBNP, and Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND) risk scores. C-statistics ranged from 0.727 for the ADHERE model to 0.767 for the ADHF/NT-proBNP score. The ADHF/NT-proBNP risk score, the ADHERE model, and the ASCEND risk score, but not the GWTG risk score, were also well calibrated. Sensitivity and PPV were modest at the >30% risk threshold and ranged from 55% for the ADHF/NT-proBNP risk score to 38.8% for the ADHERE model and from 46.7% for the ADHF/NT-proBNP risk score to 42.1% for the ASCEND risk score, respectively. There was a modest agreement between the risk scores in classifying the patients across risk strata or in classifying those who died as being at >30% risk of death. Although risk assessment tools work well for stratifying patients, their use in estimating the risk of mortality for individuals has limited clinical utility.

Identifiants

pubmed: 32464319
pii: S0895-4356(19)31015-7
doi: 10.1016/j.jclinepi.2020.05.020
pii:
doi:

Substances chimiques

Peptide Fragments 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

38-46

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Domenico Scrutinio (D)

Department of Cardiology, Istituti Clinici Scientifici Maugeri, I.R.C.C.S, Pavia, Italy. Electronic address: domenico.scrutinio@icsmaugeri.it.

Pietro Guida (P)

Department of Cardiology, Istituti Clinici Scientifici Maugeri, I.R.C.C.S, Pavia, Italy.

Enrico Ammirati (E)

Department of Cardiology, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.

Fabrizio Oliva (F)

Department of Cardiology, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy.

Andrea Passantino (A)

Department of Cardiology, Istituti Clinici Scientifici Maugeri, I.R.C.C.S, Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH